Global GLP-1 Sales Forecast Raised to $150B by 2030; Novo Nordisk at 31%
NVO•Global GLP-1 sales will reach $150B by 2030, up from $139B, driven by an expected 59M patients that will offset lower treatment prices. Novo Nordisk’s Wegovy and Ozempic are projected to capture 31% of the market, while oral GLP-1s rise to 14% of sales.
1. Upward Revision of GLP-1 Sales Forecast
Analysts raised the 2030 global GLP-1 sales outlook to $150 billion from $139 billion, driven by an anticipated 59 million patients worldwide that will offset lower treatment prices.
2. Novo Nordisk Market Share Outlook
Novo Nordisk’s Wegovy and Ozempic therapies are expected to secure 31% of the GLP-1 market by 2030, maintaining its position alongside Eli Lilly’s 62% share in the projected duopoly.
3. Growth of Oral GLP-1 Therapies
Oral GLP-1 formats are forecast to reach 14% of total sales, up from 11%, as the daily Wegovy pill launch accelerates patient adoption before competitors’ market entries.
